| Literature DB >> 28148775 |
Evgenia Salta1,2, Bart De Strooper3,2,4.
Abstract
With the consideration of the broad involvement of microRNAs (miRNAs) in the regulation of molecular networks in the brain, it is not surprising that miRNA dysregulation causes neurodegeneration in animal models. miRNA profiling in the human brain has revealed miR-132 as one of the most severely down-regulated miRNAs at the intermediate and late Braak stages of Alzheimer's disease (AD), as well as in other neurodegenerative disorders. Suppression of miR-132 aggravates multiple layers of pathology at the molecular and functional level. We describe the potential therapeutic implications of these findings and suggest miRNA targeting or replacement as a realistic multi-hit, therapeutic strategy for AD. Salta, E., De Strooper, B. microRNA-132: a key noncoding RNA operating in the cellular phase of Alzheimer's disease. © FASEB.Entities:
Keywords: amyloid/TAU pathology; neurodegeneration; neuroprotection; small RNA; therapy
Mesh:
Substances:
Year: 2017 PMID: 28148775 DOI: 10.1096/fj.201601308
Source DB: PubMed Journal: FASEB J ISSN: 0892-6638 Impact factor: 5.191